Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.56 |
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16343063 | 1.00 | CASP3 (0.56) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL16218324 | 1.00 | CASP3 (0.56) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL29907963 | 1.00 | CASP3 (0.56) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL15083102 | 0.88 | TLR2 (0.61) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL29540527 | 0.88 | TLR2 (0.61) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL29540551 | 0.88 | TLR2 (0.61) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL14445569 | 0.88 | TLR2 (0.61) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL14559793 | 0.88 | CASP3 (0.58) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL5385200 | 0.88 | CASP3 (0.58) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL12138344 | 0.88 | CASP3 (0.58) | CASP3MDM4TP53KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4594336-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PeptiDream Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240167070-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Ny-HYDROXY- OR Ny-AMINO-L-ASPARAGINE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-05-23 | — | — | US | disclosed |
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073605-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC. (JP) | 2024-04-04 | — | — | WO | disclosed |
| WO-2022186782-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Nγ-HYDROXY- OR Nγ-AMINO-L-ASPARAGINE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240167070-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Ny-HYDROXY- OR Ny-AMINO-L-ASPARAGINE | ANPEP, DNPEP, ASNS | CASP3 4032/4885MDM4 4553/4885TP53 3680/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | CASP3 4663/4885MDM4 1959/4885TP53 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.